Tzield Infusion Program
An infusion to delay the onset of T1D
Barbara Davis Center Clinical Infusion Program
The Barbara Davis Center is proud to be the first location in the Rocky Mountain region to offer clinical infusions of Tzield (teplizumab-mzwv) to patients who are in stage-2 type 1 diabetes. Tzield is a groundbreaking therapy which is meant to delay the onset of clinical type 1 diabetes, buying patients more time without insulin dependence. Our Tzield infusion program started in April 2023 and is open to eligible patients of the Barbara Davis Center as well as external referrals. Patients who meet criteria for infusion should schedule a preliminary consultation with a provider in our Early T1D Clinic.
Infusion Program Director
Kimber Simmons, MD
Lead Infusion Nurse
Lexie Chesshire, BSN, RN, CDCES
.jpg?sfvrsn=369125bb_2 "Tzield_Family 700px")
A Treatment to Delay the Onset of Type 1 Diabetes
Tzield is available for patients 8 years and older considered to be in stage-2 of type 1 diabetes. This treatment is now available at the Barbara Davis Center though the Early T1D Clinic.
Tzield (teplizumab-mzwv)
Tzield (teplizumab-mzwv) is the first and only therapy approved by the FDA to delay of the clinical onset (stage-3) of type 1 diabetes. The drug was brought to market by Provention Bio (now part of Sanofi), a pharmaceutical company focused on treatments for autoimmune diseases. Tzield was extensively studied through multiple clinical trials before receiving approval from the FDA in November 2022. In clinical trials, Tzield was shown to delay the median onset of clinical type 1 diabetes by 25 months, providing patients additional time during which they do not need to inject insulin and providing them more time to prepare for the challenges associated with living with type 1 diabetes.
Receiving Tzield requires meeting certain clinical indications which will be assessed by your doctor. The infusion regimen is completed over 14 days, consecutively, and each infusion visit takes approximately 3-4 hours.
